<p><strong>Coagulopathy</strong>: Anticoagulant response should be monitored (e.g. INR) and anticoagulant dose must be adjusted accordingly. Otherwise may result in bleeding, death.<br />
<br />
<strong>Diarrhea</strong>: Capecitabine treatment should be stopped immediately until diarrhea resolves or decreases to grade 1. Standard antidiarrheal treatments recommended. Otherwise may get severe.<br />
<br />
<strong>Cardiotoxicity</strong>: Common in patients with a prior history of coronary artery disease.<br />
<br />
<strong>Increased Risk of Severe or Fatal Adverse Reactions in Patients with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) Activity</strong>: Capecitabine should be withhold or permanently discontinued in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity.<br />
<br />
<strong>Dehydration and Renal Failure</strong>: Capecitabine treatment should be stopped until dehydration is corrected. Potential risk of acute renal failure secondary to dehydration.<br />
<br />
<strong>Mucocutaneous and Dermatologic Toxicity</strong>: Severe mucocutaneous reactions, Steven-Johnson Syndrome. (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Capecitabine should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. Capecitabine may induce hand-and-foot syndrome. Capecitabine treatment should be interrupted until the hand-and-foot syndrome event resolves or decreases in intensity.<br />
<br />
<strong>Hyperbilirubinemia</strong>: Capecitabine treatment should be interrupted immediately until the hyperbilirubinemia resolves or decreases in intensity.<br />
<br />
<strong>Hematologic</strong>: Patients should not be treated with neutrophil counts &lt;1.5x109/L or thrombocyte counts &lt;100x109/L.</p>